1 / 25

Stop Stock-outs! Access to Medicines for All! anti-counterfeiting initiatives and

Stop Stock-outs! Access to Medicines for All! anti-counterfeiting initiatives and other access barriers. Christa Cepuch OSI AEM Initiative – CS Role and Response 09 December 2009, Lusaka. Outline. WHO essential medicines concept Medicines access and stock-outs / low availability in Africa

avak
Télécharger la présentation

Stop Stock-outs! Access to Medicines for All! anti-counterfeiting initiatives and

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stop Stock-outs! Access to Medicines for All! anti-counterfeiting initiatives and other access barriers Christa Cepuch OSI AEM Initiative – CS Role and Response 09 December 2009, Lusaka

  2. Outline • WHO essential medicines concept • Medicines access and stock-outs / low availability in Africa • What are the barriers to access? • The journey of a pill: • R&D • Intellectual Property • Regulation • Generics vs counterfeits vs substandard medicines • Addressing initiatives which may affect stock-outs / low availability… anti-counterfeiting initiatives

  3. What are essential medicines? • satisfy the priority health care needs of the population • selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness • intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford • implementation of the concept of essential medicines is intended to be flexible • exactly which medicines are regarded as essential remains a national responsibility www.who.int/medicines

  4. Availability of essential medicines • Average availability in Africa is only 38% in the public sector and 59% in the private sector. • Public sector availability of medicines is consistently lower than in the private sector.

  5. Barriers to access • Health system capacity • Health budgets • Lack of research and development • Price • Patents • Quality of diagnosis • Accurate prescribing • Selection, distribution, dispensing of medicines • Medicine quality

  6. Price of essential medicines • Lowest-priced generic medicines cost 6.4 and 2.5 times international reference prices(IRPs) in the private and public sectors, respectively. • Add-on costs in the supply chain can more than double medicine prices in the private sector. Public sector mark-ups can also be substantial.

  7. Barriers to access • Health system capacity • Health budgets • Lack of research and development • Price • Patents • Quality of diagnosis • Accurate prescribing • Selection, distribution, dispensing of medicines • Medicine quality

  8. Public expenditure on medicines There is wide variation in national per capita spending on medicines by the public sector, ranging from US $0.04 to $187.30 among developing countries.

  9. Increased financial support and differential pricing can have a dramatic impact on medicine availability Availability of Artemether/lumefantrine 20/120 mg in Kenya Global Fund grant start date (02/2006)

  10. Barriers to access • Health system capacity • Health budgets • Lack of research and development • Price • Patents • Quality of diagnosis • Accurate prescribing • Selection, distribution, dispensing of medicines • Medicine quality

  11. R&D: for real health needs? • 1975-1999: 1,393 new chemical entities (NCEs) marketed; only 1% of new medicines developed were for neglected diseases • 1999-2004: 163 NCEs, including 3 new medicines for neglected diseases Trouiller et al., Lancet 2002, 359:2188-94; updated figures: Torreele, Chirac 2005

  12. Barriers to access • Health system capacity • Health budgets • Lack of research and development • Price • Patents • Quality of diagnosis • Accurate prescribing • Selection, distribution, dispensing of medicines • Medicine quality

  13. ‘Patents constitute a temporary monopoly, but in the end society benefits’ Fred Hassan, CEO of Schering-Plough and president of IFPMA 10 Oct 2006 Which society benefits?

  14. 20 year patent on medicines • 1995: WTO TRIPS Agreement outlines the “minimum standards” for national legislation on IP – concern arose on the effect of TRIPS on access to essential medicines • 2001: WTO Ministerial Doha Declaration on TRIPS and Public Health“… TRIPS …does not and should not prevent… measures to protect public health…”

  15. Generic medicines • Equivalent copy of an originator medicine • Undergoes strict scrutiny before it is licensed and given market approval by the NMRA • In Africa, health systems and budgets depend on generic medicines • PEPFAR’s purchase of generic ARVs resulted in cost-savings up to 90%

  16. Effect of Generic Competition Effect of generic competition Source: http://www.msfaccess.org/fileadmin/user_upload/diseases/hivaids/Untangling_the_Web/Untanglingtheweb_July2008_English.pdf www.msfaccess.org

  17. Barriers to access • Health system capacity • Health budgets • Lack of research and development • Price • Patents • Quality of diagnosis • Accurate prescribing • Selection, distribution, dispensing of medicines • Medicine quality

  18. Substandard medicines • “genuine” medicines which do not meet quality specifications set for them • contamination (impurity) • too much active ingredient (toxicity) or too little active ingredient (ineffective treatment; resistance) • Failure may be due to • poor manufacturing, storage and / or distribution conditions (accidental or lack of resources / expertise) • weak medicines regulatory agencies • lack of information / reporting

  19. Sub-standard AMs in Kenya: a sampling of studies

  20. Anti-counterfeit initiatives: a NEW barrier to access?? • Health system capacity • Health budgets • Lack of research and development • Price • Patents • Quality of diagnosis • Accurate prescribing • Selection, distribution, dispensing of medicines • Medicine quality • Anti-Counterfeit initiatives…?!!?!!

  21. Counterfeit medicines: definitions • WTO TRIPS: trademark infringement • WHO: • deliberately and fraudulently mislabeled with respect to identity and / or source • can apply to both brand and generic medicines • may include medicines with the correct active ingredients, with insufficient active ingredients or with fake packaging • IMPACT… • Country legislations…

  22. Advocating for public-health friendly Anti-Counterfeit initiatives • Kenya ongoing efforts to address the Act’s weaknesses (attempting amendments; supporting the Constitutional Court case; media) • Uganda collaborative efforts to improve the draft Bill • Tanzania identifying issues and finding partners • Zambia CSO meeting 11 Dec • Ghana...? South Africa...? Zimbabwe…? • other countries? • EAC Policy on IPRs and Anti-Counterfeiting

More Related